ABSTRACT
Antitumor Activity In Vivo ................................................................................................ 558 29.9 PHY906 Clinical Trials ...................................................................................................... 558 29.10 Detection of PHY906 Chemicals or Their Metabolites in the Plasma of Patients
Following PHY906 Treatment ............................................................................................ 558 29.11 Summary ............................................................................................................................560 Acknowledgments ..........................................................................................................................560 References ......................................................................................................................................560
Cancer is the second-largest killer in the United States, killing around 571,950 Americans annually or more than 1500 people a day in 2011. It means almost one of every four deaths is due to cancer (American Cancer Society 2011). At the same time, there are over 1.5 million new diagnoses of cancer annually (American Cancer Society 2011). Despite billions of dollars being spent annually to develop new cancer therapies to treat cancer, the overall 5-year relative survival rate for all diagnosed cancers has only increased by 18% from the 1970s to the 2000s (American Cancer Society 2011). Some types of cancer, such as those of the pancreas or liver, have only 6% and 14% 5-year survival rates, respectively (American Cancer Society 2011).
